Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review
Journal of the American Heart Association · 15.08.2023 · 12 (16)
DOI: 10.1161/jaha.123.030578 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of the American Heart Association, erschienen am 15.08.2023. Verfasst von Hammad Rahman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology Guthrie Robert Packer Hospital Sayre PA. Hauptthemen laut MEDLINE: Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Myocardial Infarction. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors reduce atherosclerotic cardiovascular disease (ASCVD) events in patients with prior ASCVD and type 2 diabetes; however, this benefit is uncertain in patients without established ASCVD. Methods and Results Large‐scale cardiovascular outcome randomized controlled trials or their prespecified subgroup analyses were selected, evaluating SGLT2 inhibitors versus placebo for primary prevention of ASCVD (inception, March 2023). The primary outcome was atherosclerotic major adverse cardiovascular events (MACEs), which was a composite of cardiovascular mortality, myocardial infarction, and stroke. The secondary outcomes were individual components of MACEs and all‐cause mortality. The outcomes were reported as random‐effect relative risk (RR) with a 95% CI. This analysis, comprising 23 987 patients enrolled in 5 randomized controlled trials with a mean follow‐up duration of ≈135 weeks, found no significant reduction in atherosclerotic MACEs with SGLT2 inhibitors in comparison to placebo (RR, 0.85 [95% CI, 0.71–1.01]; P =0.07; I 2 =44). There were no significant differences in cardiovascular mortality (RR, 0.93 [95% CI, 0.77–1.14]; P =0.50; I 2 =0), myocardial infarction (RR, 0.88 [95% CI, 0.69–1.11]; P =0.28; I 2 =23), and stroke (RR, 0.84 [95% CI, 0.62–1.16]; P =0.29; I 2 =46). SGLT2 inhibitors significantly improved all‐cause mortality (RR, 0.85 [95% CI, 0.72–1.0]; P =0.04; I 2 =23). On subgroup analyses, the use of SGLT2 inhibitors led to significant reductions in MACEs (RR, 0.74 [95% CI, 0.61–0.89]; P =0.001), myocardial infarction (RR, 0.67 [95% CI, 0.47–0.97]; P =0.03), and stroke (RR, 0.61 [95% CI, 0.41–0.91]; P =0.01) primarily in patients with chronic kidney disease along with type 2 diabetes, whereas these benefits were not observed in patients with type 2 diabetes without chronic kidney disease.
Conclusions
SGLT2 inhibitors significantly reduced atherosclerotic MACEs in subjects having both chronic kidney disease and type 2 diabetes without established ASCVD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology Guthrie Robert Packer Hospital Sayre PA.
- Division of Cardiology Methodist Hospital Houston TX.
- Department of Medicine Guthrie Robert Packer Hospital Sayre PA.
- Division of Cardiology Guthrie Health System/Robert Packer Hospital Sayre PA.
- Division of Cardiology Rutgers New Jersey Medical School Newark NJ.
- Division of Cardiology The Geisinger Commonwealth Medical College Scranton PA.
ORCID-Profile: Hammad Rahman, Safi U Khan, Saurabh Sharma, Edo Kaluski
Zitieren
APA
Rahman, H., Khan, S. U., Lone, A. N., Ghosh, P., Kunduru, M., Sharma, S., Sattur, S., & Kaluski, E. (2023). Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review. Journal of the American Heart Association, 12(16). https://doi.org/10.1161/jaha.123.030578
Vancouver
Rahman H, Khan SU, Lone AN, Ghosh P, Kunduru M, Sharma S, et al. Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review. Journal of the American Heart Association. 2023;12(16). doi:10.1161/jaha.123.030578
BibTeX
@article{Rahman2023,
author = {Rahman, Hammad and Khan, Safi U and Lone, Ahmad N and Ghosh, Priyanka and Kunduru, Mahathi and Sharma, Saurabh and Sattur, Sudhakar and Kaluski, Edo},
title = {Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review},
journal = {Journal of the American Heart Association},
year = {2023},
volume = {12},
number = {16},
doi = {10.1161/jaha.123.030578}
}
EUVIMED